Crystal structures of Escherichia coli uridine phosphorylase in two native and three complexed forms reveal basis of substrate specificity, induced conformational changes and influence of potassium

Journal of Molecular Biology

Volumn 337, Issue 2, 2004, Pages 337-354

  Caradoc Davies, Tom T ^a   Cutfield, Sue M ^a   Lamont, Iain L ^a   Cutfield, John F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

5 fluorouracil; 5FU, 5 fluorouracil; Induced fit; PNP, purine nucleoside phosphorylase; Potassium; Specificity; UP, uridine phosphorylase; Uridine phosphorylase

Indexed keywords

ARGININE; BACTERIAL ENZYME; DEOXYURIDINE DERIVATIVE; FLUOROURACIL; GLUTAMINE; PHOSPHATE; POTASSIUM ION; RIBOSE; RIBOSE 1 PHOSPHATE; THYMIDINE; URACIL; URIDINE PHOSPHORYLASE;

ARTICLE; BACTERIAL STRAIN; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL;

ESCHERICHIA COLI; PHOCIDAE;

EID: 1442348235     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.01.039     Document Type: Article

References (67)

1. Pugmire M.J., Ealick S.E. Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem. J. 361:2002;1-25.
2. Leyva A., van Groeningen C.J., Kraal I., Gall H., Peters G.J., Lankelma J., Pinedo H.M. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res. 44:1984;5928-5933.
3. van Groeningen C.J., Leyva A., Kraal I., Peters G.J., Pinedo H.M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Treat. Rep. 70:1986;745-750.
4. Ashour O.M., Naguib F.N.M., Panzica R.P., Al Safarjalani O.N., el Kouni M.H. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl) barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2′3′5′-tri-O-acetyluridine, a prodrug of uridine. Biochem. Pharmacol. 60:2000;427-431.
5. Pizzorno G., Yee L., Burtness B.A., Marsh J.C., Darnowski J.W., Chu M.Y.W., et al. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin. Cancer Res. 4:1998;1165-1175.
6. Ealick S.E., Rule S.A., Carter D.C., Greenhough T.J., Babu Y.S., Cook W.J., et al. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 Å resolution. J. Biol. Chem. 265:1990;1812-1820.
7. Koellner G., Luić M., Shugar D., Saenger W., Bzowska A. Crystal structure of calf spleen purine nucleoside phosphorylase in a complex with hypoxanthine at 2.15 Å resolution. J. Mol. Biol. 265:1997;202-216.
8. Mao C., Cook W.J., Zhou M., Koszalka G.W., Krenitsky T.A., Ealick S.E. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 5:1997;1373-1383.
9. Shi W., Basso L.A., Santos D.S., Tyler P.C., Furneaux R.H., Blanchard J.S., Almo S.C., Schramm V.L. Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces. Biochemistry. 40:2001;8204-8215.
10. Tebbe J., Bzowska A., Wielgus-Kutrowska B., Schröder W., Kazimierczuk Z., Shugar D., et al. Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism for trimeric PNPs. J. Mol. Biol. 294:1999;1239-1255.
11. Morgunova E.Y., Mikhailov A.M., Popov A.N., Blagova E.V., Smirnova E.A., Vainshtein B.K., et al. Atomic structure at 2.5 Å resolution of uridine phosphorylase from E. coli as refined in the monoclinic lattice. FEBS Letters. 367:1995;183-187.
12. Burling F.T., Kniewel R., Buglino J.A., Chadha T., Beckwith A., Lima C.D. Structure of Escherichia coli uridine phosphorylase at 2.0 Å resolution. Acta Crystallog. sect. D. 59:2003;73-76.
13. Walter M.R., Cook W.J., Cole L.B., Short S.A., Koszalka G.W., Krenitsky T.A., Ealick S.E. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 Å resolution. J. Biol. Chem. 265:1990;14016-14022.
14. Pugmire M.J., Cook W.J., Jasanoff A., Walter M.R., Ealick S.E. Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. J. Mol. Biol. 281:1998;285-299.
15. Pugmire M.J., Ealick S.E. The crystal structure of pyrimidine nucleoside phosphorylase in a closed conformation. Structure. 6:1998;1467-1479.
16. Erion M.D., Niwas S., Rose J.D., Ananthan S., Allen M., Secrist J.A. III, et al. Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the methylene group. J. Med. Chem. 36:1993;3771-3783.
17. Bzowska A., Kulikowska E., Shugar D. Formycins A and B and some analogues: selective inhibitors of bacterial (Escherichia coli) purine nucleoside phosphorylase. Biochim. Biophys. Acta. 1120:1992;239-247.
18. Miles R.W., Tyler P.C., Furneaux R.H., Bagdassarian C.K., Schramm V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 37:1998;8615-8621.
19. Shi W., Li C.M., Tyler P.C., Furneaux R.H., Cahill S.M., Girvin M.E., et al. The 2.0 Å structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor. Biochemistry. 38:1999;9872-9880.
20. Shi W., Munagala N.R., Wang C.C., Li C.M., Tyler P.C., Furneaux R.H., et al. Crystal structures of Giardia lamblia guanine phosphoribosyltransferase at 1.75 Å Biochemistry. 39:2000;6781-6790.
21. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763.
22. Fedorov A., Shi W., Kicska G., Fedorov E., Tyler P.C., Furneaux R.H., et al. Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. Biochemistry. 40:2001;853-860.
23. Koellner G., Luić M., Shugar D., Saenger W., Bzowska A. Crystal structure of the ternary complex of E. coli purine nucleoside phosphorylase with formycin B, a structural analogue of the substrate inosine, and phosphate (sulphate) at 2.1 Å resolution. J. Mol. Biol. 280:1998;153-166.
24. Kline P.C., Schramm V.L. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry. 32:1993;13212-13219.
25. Koellner G., Bzowska A., Wielgus-Kutrowska B., Luić M., Steiner T., Saenger W., Stepiński J. Open and closed conformation of the E. coli purine nucleoside phosphorylase active center and implications for the catalytic mechanism. J. Mol. Biol. 315:2002;351-371.
26. Kraut A., Yamada E.W. Cytoplasmic uridine phosphorylase of rat liver. J. Biol. Chem. 246:1971;2021-2030.
27. Liu M., Cao D., Russel R., Handshumacher R.E., Pizzorno G. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res. 58:1998;5418-5424.
28. Vita A., Huang C.Y., Magni G. Uridine phosphorylase from Escherichia coli B.: kinetic studies on the mechanism of catalysis. Arch. Biochem. Biophys. 226:1983;687-692.
29. Vita A., Amici A., Cacciamani T., Lancotti M., Magni G. Uridine phosphorylase from Escherichia coli B. Enzymatic and molecular properties. Int. J. Biochem. 18:1986;431-436.
30. Krenitsky T.A. Uridine phosphorylase from Escherichia coli. Kinetic properties and mechanism. Biochem. Biophys. Acta. 429:1976;352-358.
31. Harding M.J. Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. Acta Crystallog. sect. D. 58:2002;872-874.
32. Kelly J.L., McLean E.W., Crouch R.C., Averett D.R., Tuttle J.V. [[(Guaninylalkyl)phosphinico]methyl]phosphonic acids. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase. J. Med. Chem. 38:1995;1005-1014.
33. Leer J.C., Hammer-Jespersen K., Schwartz M. Uridine phosphorylase from Escherichia coli. Physical and chemical characterization. Eur. J. Biochem. 75:1977;21.
34. Kline P.C., Schramm V.L. Pre-steady-state transition-state analysis of the hydrolytic reaction catalysed by purine nucleoside phosphorylase. Biochemistry. 34:1995;1153-1162.
35. Basso L.A., Santos D.S., Shi W., Furneaux R.H., Tyler P.C., Schramm V.L., Blanchard J.S. Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition by a transition-state analogue and dissection by parts. Biochemistry. 40:2001;8196-8203.
36. Kicska G.A., Tyler P.C., Evans G.B., Furneaux R.H., Shi W., Federov A., et al. Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry. 41:2002;14489-14498.
37. Schramm V.L. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochem. Biophys. Acta. 1587:2002;107-117.
38. Erion M.D., Stoeckler J.D., Guida W.C., Walter R.L., Ealick S.E. Purine nucleoside phosphorylase. 2. Catalytic mechanism. Biochemistry. 36:1997;11735-11748.
39. Erion M.D., Takabayashi K., Smith H.B., Kessi J., Wagner S., Hönger S., et al. Purine nucleoside phosphorylase. 1 Structure-function studies. Biochemistry. 36:1997;11725-11734.
40. Stoeckler J.D., Poirot A.F., Smith R.M., Parks R.E. Jr, Ealick S.E., Takabayashi K., Erion M.D. Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis. Biochemistry. 36:1997;11749-11756.
41. Blow D.M., Birktoft J.J. Hartley role of a buried acid group in the mechanism of action of chymotrypsin. Nature. 221:1969;337-340.
42. Niedzwicki J.G., Chu S.H., El Kouni M.H., Rowe E.C., Cha S. 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem. Pharmacol. 31:1982;1857-1861.
43. el Kouni M.H., Goudgaon N.M., Rafeeq M., Al Safarjalani O.N., Schinazi R.F., Naguib F.N.M. 5-Phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase. Biochem. Pharmacol. 60:2000;851-856.
44. Davis A.M., Teague S.J., Kleywegt G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. 42:2003;2718-2736.
45. Magni G. Uridine nucleosidase from yeast. Methods Enzymol. 26:1978;290-296.
46. Minor, W. (1993). XDISPLAYF In The HKL Manual, HKL Research, Inc., Charlottesville, VA.
47. Otwinowski Z. Oscillation data reduction program. Sawyer L., Isaacs N., Bailey S. Proceedings of the CCP4 Study Weekend: Data Collection and Processing 29-30 January. 1993;56-62 SERC Daresbury Laboratory, England.
48. Leslie A.G.W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 ESF-EAMCB Newsletter Protein Crystallog. 26:1992;7-224.
49. Evans P.R. Data reduction. Proc. CCP4 Study Weekend. 1993:1993;114-122.
50. French G.S., Wilson K.S. On the treatment of negative intensity observations. Acta Crystallog. sect. A. 34:1978;517.
51. Howell L., Smith D. Normal probability analysis. J. Appl. Crystallog. 25:1992;81.
52. Kraut J., Sieker L.C., High D.F., Freer S.T. Chymotrypsinogen: a three-dimensional Fourier synthesis at 5 Å resolution. Proc. Natl Acad. Sci. USA. 48:1962;1417-1424.
53. Immirzi A. Ahmed F.R. Crystallographic Computing Techniques. 1966;399. Munksgaard, Copenhagen.
54. Knight S.D. RSPS version 4.0: a semi-interactive vector-search program for solving heavy-atom derivatives. Acta Crystallog. sect. D. 52:2000;42-47.
55. Cowtan K. dm: an automated procedure for phase improvement by density modification. Joint CCP4 ESF-EACBM Newsletter Protein Crystallog. 31:1994;34-38.
56. McRee D.E. A visual protein crystallographic software system for X11/XView. J. Mol. Graph. 10:1992;44-46.
57. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D. 53:1997;240-255.
58. Brunger A.T., Adams P.D., Clore G.M., Delano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR System: a new software system for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
59. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallog. sect. A. 50:1994;157-163.
60. Gordon J.A. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 201:1991;477-482.
61. Arvai A.S., Bourne Y., Hickey M.J., Tainer J.A. Crystal structure of the human cell cycle protein CksHs1: single domain fold with similarity to kinase N-lode domain. J. Mol. Biol. 249:1995;835-842.
62. Vaguine A.A., Richelle J., Wodak S.J. SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with atomic model. Acta Crystallog. sect. D. 55:1999;191-205.
63. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283.
64. Luzzati V. Traitement statistique des erreurs dans la determination des structures crisallines. Acta Crystallog. 5:1952;802-810.
65. Read R.J. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallog. sect. A. 42:1986;140-149.
66. Merritt E.A., Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524.
67. DeLano W.L. The PyMOL Molecular Graphics System. 2003;DeLano Scientific LLC, San Carlos, CA, USA. http://www.pymol.org.